45 research outputs found
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Engineering Periodic shRNA for Enhanced Silencing Efficacy
RNA interference (RNAi) provides a versatile therapeutic approach via silencing of specific genes, particularly undruggable targets in cancer and other diseases. However, challenges in the delivery of small interfering RNA (siRNA) have hampered clinical translation. Polymeric or periodic short hairpin RNAs (p-shRNAs) - synthesized by enzymatic amplification of circular DNA - are a recent development that can potentially address these delivery barriers by showing improved stability and complexation to enable nanoparticle packaging. Here, we modify these biomacromolecules via structural and sequence engineering coupled with selective enzymatic digestion to generate an open-ended p-shRNA (op-shRNA) that is cleaved over ten times more efficiently to yield siRNA. The op-shRNA induces considerably greater gene silencing than p-shRNA in multiple cancer cell lines up to 9 days. Furthermore, its high valency and flexibility dramatically improve complexation with a low molecular weight polycation compared to monomeric siRNA. Thus, op-shRNA provides an RNAi platform that can potentially be packaged and efficiently delivered to disease sites with higher therapeutic efficacy
Real-Time Observation of the Defect Dynamics in Working Au/CeO<sub>2</sub> Catalysts by Combined Operando Raman/UV–Vis Spectroscopy
Supported gold catalysts
are highly active for a variety of reactions
including low-temperature CO oxidation. It has been shown that reducible
support materials, e.g., ceria or titania, may significantly alter
the catalytic performance. In this contribution, we provide the first
direct evidence for ceria (CeO<sub>2</sub>) support dynamics and its
relevance in Au/CeO<sub>2</sub> catalysts during room temperature
CO oxidation. In particular, combined operando Raman and UV–vis
spectroscopy are employed to monitor the surface and subsurface defect
dynamics of ceria quantitatively and in real time. The results clearly
show a dependence of catalytic activity on the reduction state of
the ceria support. In fact, the prereduced CeO<sub>2</sub> catalyst
support increases the activity during CO oxidation initially by 100%.
The reduction is not limited to the CeO<sub>2</sub> surface but also
affects the CeO<sub>2</sub> subsurface due to oxygen mobility and
charge transfer in CeO<sub>2–<i>x</i></sub>. Our
results highlight the enormous importance of the support properties
for a mechanistic understanding of oxidation reactions over metal/ceria
catalyst materials
Rationally Designed Polycationic Carriers for Potent Polymeric siRNA-Mediated Gene Silencing
The delivery of small interfering RNA (siRNA) remains a major hurdle for the clinical translation of RNA interference (RNAi) therapeutics. Because of its low valency and rigid nature, siRNA typically requires high excesses of cationic delivery materials to package it stably and deliver it to the cytoplasm of target cells, resulting in high toxicities and inefficient gene silencing in vivo. To address these challenges, we pair a polymeric form of siRNA, p-shRNA, with optimized biodegradable polycations to form stable complexes that induce far more potent gene silencing than with siRNA complexes. Furthermore, we unveil a set of design rules governing p-shRNA delivery, using degradable polycations containing hydrophobic and stabilizing polyethylene glycol domains that enable both stable condensation and efficient release inside cells. We demonstrate the therapeutic potential of this approach by silencing the oncogene STAT3 in a well-established B16F10 mouse melanoma model to significantly prolong survival. By blending nucleic acid engineering and polymer design, our system provides a potentially translatable platform for RNAi-based therapies. Keywords: RNA interference; polycation; gene delivery; siRNA; poly(beta-amino ester)Congressionally Directed Medical Research Programs (U.S.) (Award 13–1-0151, PTH
Rationally Designed Polycationic Carriers for Potent Polymeric siRNA-Mediated Gene Silencing
The
delivery of small interfering RNA (siRNA) remains a major hurdle
for the clinical translation of RNA interference (RNAi) therapeutics.
Because of its low valency and rigid nature, siRNA typically requires
high excesses of cationic delivery materials to package it stably
and deliver it to the cytoplasm of target cells, resulting in high
toxicities and inefficient gene silencing <i>in vivo</i>. To address these challenges, we pair a polymeric form of siRNA,
p-shRNA, with optimized biodegradable polycations to form stable complexes
that induce far more potent gene silencing than with siRNA complexes.
Furthermore, we unveil a set of design rules governing p-shRNA delivery,
using degradable polycations containing hydrophobic and stabilizing
polyethylene glycol domains that enable both stable condensation and
efficient release inside cells. We demonstrate the therapeutic potential
of this approach by silencing the oncogene STAT3 in a well-established
B16F10 mouse melanoma model to significantly prolong survival. By
blending nucleic acid engineering and polymer design, our system provides
a potentially translatable platform for RNAi-based therapies
Polyamine-Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery
Messenger RNA (mRNA) represents a promising class of nucleic acid drugs. Although numerous carriers have been developed for mRNA delivery, the inefficient mRNA expression inside cells remains a major challenge. Inspired by the dependence of mRNA on 3′-terminal polyadenosine nucleotides (poly A) and poly A binding proteins (PABPs) for optimal expression, we complexed synthetic mRNA containing a poly A tail with PABPs in a stoichiometric manner and stabilized the ribonucleoproteins (RNPs) with a family of polypeptides bearing different arrangements of cationic side groups. We found that the molecular structure of these polypeptides modulates the degree of PABP-mediated enhancement of mRNA expression. This strategy elicits an up to 20-fold increase in mRNA expression in vitro and an approximately fourfold increase in mice. These findings suggest a set of new design principles for gene delivery by the synergistic co-assembly of mRNA with helper proteins.United States. Department of Defense. Ovarian Cancer Research Program.United States. Department of Defense. Peer Reviewed Orthopaedic Research Program